PLIANT THERAPEUTICS, INC.
About PLIANT THERAPEUTICS, INC.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$149.3M
- Total assets
- $225.2M
- Market cap
- $71.2M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $156.4M
- Operating income
- -$156.4M
- Income tax
- $0
- Net income
- -$149.3M
- EPS (basic)
- $-2.43
- EPS (diluted)
- $-2.43
Balance sheet
- Total assets
- $225.2M
- Current assets
- $196.4M
- Total liabilities
- $44.0M
- Current liabilities
- $16.4M
- Shareholders’ equity
- $181.2M
Cash flow
- Operating cash flow
- -$128.3M
- Investing cash flow
- $134.3M
- Financing cash flow
- -$31.7M
- Net cash flow
- -$25.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $71.2M
- EPS (diluted)
- $-2.43
- Shares outstanding
- 61.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 3, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $149.3M in FY2025.
- Trading 39% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review PLIANT THERAPEUTICS, INC..
Write a review
News about PLIANT THERAPEUTICS, INC.
News & sentiment via Polygon.io
